PURPOSE: To highlight a new imaging acquisition protocol during @entity9242 PET/CT in @entity1 with biochemical recurrence after @entity6391 . METHODS: A total of 146 @entity1 with PSA levels between 0.2 and 1  ng/ml with negative conventional imaging who did not receive salvage treatment were prospectively enrolled. Imaging acquisition protocol included an early dynamic phase (1-8  min), a conventional whole body (10-20  min), and a late phase (30-40  min). Sensitivity, specificity, positive predictive value ( @entity2286 ), and negative predictive value (NPV) were measured. Univariable and multivariable analyses were performed to identify independent predictors of positive PET/CT. RESULTS: The median trigger PSA was 0.6  ng/ml (IQR 0.43-0.76). Median PSA doubling time (PSA DT) was 7.91  months (IQR 4.42-11.3); median PSA velocity (PSAV) was 0.02  ng/ml per month (IQR 0.02-0.04). Overall, @entity9242 PET/CT was positive in 111 of 146 @entity1 (76  %). Out of 111 positive examinations, 80 (72.1  %) were positive only in the early dynamic phase. Sensitivity, specificity, @entity2286 , NPV, and accuracy were 78.9, 76.9, 97.2, 26.3, and 78.7  %, respectively. At multivariable logistic regression, trigger PSA  >=   0.6  ng/ml [odds ratio (OR) 3.13; p  =  0.001] and PSAV  >=   0.04  ng/ml per month (OR 4.95; p  =  0.004) were independent predictors of positive PET/CT. The low NPV remains the main limitation of PET/CT in this setting of @entity1 . CONCLUSIONS: The increased sensitivity, thanks to the early imaging acquisition protocol, makes @entity9242 PET/CT an attractive tool to detect @entity263 recurrences in @entity1 with a PSA level <1  ng/ml.

Significant XXXX recurrence following radical prostatectomy with an early imaging acquisition protocol with @entity9242 positron emission tomography/computed tomography.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity2286 :: ('12211', 'Species') :: ['PPV'] @entity9242 :: ('MESH:C514960', 'Chemical') :: ['(18)F-fluorocholine'] @entity6391 :: ('MESH:D012174', 'Disease') :: ['RP']
@entity263 :: (MESH:D011471,Disease) :: ['increase in detection of prostate cancer']
